Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds

J Immunol. 2014 Dec 1;193(11):5733-43. doi: 10.4049/jimmunol.1301769. Epub 2014 Oct 31.

Abstract

Adoptive transfer of Ag-specific T lymphocytes is an attractive form of immunotherapy for cancers. However, acquiring sufficient numbers of host-derived tumor-specific T lymphocytes by selection and expansion is challenging, as these cells may be rare or anergic. Using engineered T cells can overcome this difficulty. Such engineered cells can be generated using a chimeric Ag receptor based on common formats composed from Ag-recognition elements such as αβ-TCR genes with the desired specificity, or Ab variable domain fragments fused with T cell-signaling moieties. Combining these recognition elements are Abs that recognize peptide-MHC. Such TCR-like Abs mimic the fine specificity of TCRs and exhibit both the binding properties and kinetics of high-affinity Abs. In this study, we compared the functional properties of engineered T cells expressing a native low affinity αβ-TCR chains or high affinity TCR-like Ab-based CAR targeting the same specificity. We isolated high-affinity TCR-like Abs recognizing HLA-A2-WT1Db126 complexes and constructed CAR that was transduced into T cells. Comparative analysis revealed major differences in function and specificity of such CAR-T cells or native TCR toward the same antigenic complex. Whereas the native low-affinity αβ-TCR maintained potent cytotoxic activity and specificity, the high-affinity TCR-like Ab CAR exhibited reduced activity and loss of specificity. These results suggest an upper affinity threshold for TCR-based recognition to mediate effective functional outcomes of engineered T cells. The rational design of TCRs and TCR-based constructs may need to be optimized up to a given affinity threshold to achieve optimal T cell function.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / immunology*
  • Antibody Affinity
  • Cancer Vaccines*
  • Cytotoxicity, Immunologic
  • Genetic Engineering
  • HLA-A2 Antigen / metabolism
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Jurkat Cells
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Protein Binding
  • Receptors, Antigen, T-Cell, alpha-beta / immunology*
  • Recombinant Fusion Proteins / immunology*
  • Signal Transduction
  • T-Cell Antigen Receptor Specificity
  • T-Lymphocytes / physiology*

Substances

  • Antibodies
  • Cancer Vaccines
  • HLA-A2 Antigen
  • Receptors, Antigen, T-Cell, alpha-beta
  • Recombinant Fusion Proteins